Search bioRxiv⌕ Search

Biology subjects

Vu, T.-H.

Publications and source records attributed to Vu, T.-H..

2 recordsLinked to original sources

A systematic identification of resistance determinants to antisense antibiotics suggests adaptation strategies dependent on the delivery peptide

The rise of antimicrobial resistance (AMR) among human pathogenic microbes is a serious threat to global health, calling for the development of novel treatment strategies. Antibiotics based on programmable antisense oligomers (asobiotics) offer an attractive solution to the "arms-race", as their specificity can be quickly updated and tailored to target resistant bacteria. In order to understand the genetic architecture of resistance to asobiotics, we employed laboratory evolution assays to identify mutations that decrease susceptibility to antisense peptide nucleic acid (PNA) against four major gram-negative pathogens: Escherichia coli, Klebsiella pneumoniae, Salmonella enterica, and Pseudomonas aeruginosa. We observed that the reduction in susceptibility upon asobiotics treatment was dependent on the specific cell penetrating peptide (CPP) being conjugated to the PNAs, suggesting that reduced uptake is a common adaptation strategy only against the (KFF)3-K CPP. We in fact observed that sbmA was frequently mutated in all tested species when treated with (KFF)3-K conjugated PNAs. We further identified mutations related to translation, peptide transport and cell envelope, which provide new hypotheses on cellular response to CPP-PNAs conjugates. Furthermore, for (RXR)4XB-acpP we observed a modest increase in resistance only when mutations in the PNA binding site were induced, which could easily be bypassed by changing the PNA sequence. These findings indicate that the specific identity of the CPP used plays a key role in determining its robustness against the evolution of resistance, and that laboratory evolution can illuminate the remaining gaps in our knowledge on the mechanisms of action of asobiotics.

microbiology↗

Antibiotics of the future are prone to resistance in Gram-negative pathogens

Despite the ongoing development of new antibiotics, the future evolution of bacterial resistance may render them ineffective. We demonstrate that antibiotic candidates currently under development are as prone to resistance evolution in Gram-negative pathogens as clinically employed antibiotics. Resistance generally stems from both genomic mutations and the transfer of antibiotic resistance genes from microbiomes associated with humans, both factors carrying equal significance. The molecular mechanisms of resistance overlap with those found in commonly used antibiotics. Therefore, these mechanisms are already present in natural populations of pathogens, indicating that resistance can rapidly emerge through selection of pre-existing bacterial variants. However, certain combinations of antibiotics and bacterial strains are less prone to developing resistance, emphasizing the potential of narrow-spectrum antibacterial therapies that could remain effective. Our comprehensive framework allows for predicting future health risks associated with bacterial resistance to new antibiotics.

microbiology↗